SITC connectED Patient Portal


Browse online courses and resources for patients by date published, cancer type, or general immunotherapy courses. Click the Additional Patient Resources button to explore more SITC resources for patients..


Collapse 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)

Published: On Date

 

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

 

Additional support for this activity provided by:

 

Course Description and Target Audience
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided


Estimated time to complete activity: 25 Minutes

Learning Objectives
At the conclusion of this activity, the participant should be able to:

  • Understand the patient journey and how to prepare a patient for these steps.

  • To be informed of the many time points that require patient education and reinforcement.

  • Develop an understanding about the varying pieces of education necessary for patient success.

  • How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

 

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

 

Faculty and Disclosure of Conflicts of Interest

No relevant financial conflicts.

Faculty
Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
Massachusetts General Hospital
Boston, MA

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Original Course Date: December 25, 2023

Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)
    Collapse Melanoma, v3.0 CPG Mini-Module 1– Multidisciplinary care for resectable melanoma

     

    Melanoma, v3.0 CPG Mini-Module 1– Multidisciplinary care for resectable melanoma

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, these on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

    Tina Hieken, MD, of Mayo Clinic, presents a case study of a patient with resectable melanoma and addresses benefits associated with immune checkpoint blockade therapy in the neoadjuvant and adjuvant settings. Discussion between Dr. Hieken with panelists Elizabeth Buchbinder, MD, of Dana-Farber Cancer Institute and April Salama, MD, of the Duke Cancer Institute touches on considerations for selecting appropriate treatment for patients, unanswered questions regarding neoadjuvant treatment, the need for larger clinical trials addressing immunotherapy in the neoadjuvant setting, and the importance of multidisciplinary care when treating patients with resectable disease.

     

    Run time: Approximately 11 minutes

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 


     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: December 07, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Melanoma, v3.0 CPG Mini-Module 1– Multidisciplinary care for resectable melanoma
    Collapse Gastrointestinal Cancer CPG Mini-Module 1– Immunotherapy biomarkers in the gastrointestinal tract

     

    Gastrointestinal Cancer CPG Mini-Module – Immunotherapy biomarkers in the gastrointestinal tract

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, these on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

     

    Kristen K. Ciombor, MD, MSCI, of Vanderbilt Ingram Cancer Center, Vanderbilt University, presents an overview of tumor-agnostic biomarkers including MSI-H/dMMR, POLE/POLD1 mutations, and TMB and the caveats of these biomarkers in the context of gastrointestinal cancers. Data from key clinical studies of these biomarkers are also discussed.

     

    Run time: Approximately 11 minutes

     

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

     

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 


     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: December 05, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gastrointestinal Cancer CPG Mini-Module 1– Immunotherapy biomarkers in the gastrointestinal tract
    Collapse Gastrointestinal Cancer CPG Mini-Module 2 – Patient selection for immunotherapy for esophagogastric cancer

     

    Gastrointestinal Cancer CPG Mini-Module – Patient selection for immunotherapy for esophagogastric cancer

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, these on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

     

    Geoffrey Ku, MD, of Memorial Sloan Kettering Cancer Center presents two case studies of esophagogastric cancer, illustrating how biomarkers can provide guidance for treating a patient’s individual disease. Dr. Ku also discusses key first-line clinical studies underlying the guidelines and the need to identify patient subpopulations most likely to benefit from immunotherapy. The mini-module concludes with a discussion between Dr. Ku and moderator Ronan J. Kelly, MD, MBA, of Baylor University Medical Center on specific factors to consider when treating patients with PD-L1-positive esophagogastric tumors and the caveats of PD-L1 testing.

     

    Run time: Approximately 20 minutes

     

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

     

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 


     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: December 05, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gastrointestinal Cancer CPG Mini-Module 2 – Patient selection for immunotherapy for esophagogastric cancer
    Collapse Gastrointestinal Cancer CPG Mini-Module 3 – Management of lower gastrointestinal tumors

     

    Gastrointestinal Cancer CPG Mini-Module – Management of lower gastrointestinal tumors

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, these on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

     

    Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center, addresses the guidelines in the context of tumors in the lower gastrointestinal tract by presenting a case study of multidisciplinary management of metastatic colorectal cancer. Dr. Eng also discusses important considerations when deciding between single-agent immune checkpoint blockade or combination therapy and the clinical data underlying these considerations.

     

    Run time: Approximately 15 minutes

     

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

     

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 


     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: December 05, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gastrointestinal Cancer CPG Mini-Module 3 – Management of lower gastrointestinal tumors
    Collapse 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases

    Published Date: 12/01/2023

    Expiration Date: 12/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. In the course Difficult-to-treat Cases, Subject Matter Expert- David A. Braun, MD, PhD of Yale School of Medicine has endorsed the effectiveness of Immunotherapy in treating patients with Renal Cell Carcinoma. There are 3 real life difficult to treat case scenarios that elaborate tests, treatment plans, and the outcomes. The Subject Matter Expert reinforced his treatment plans while sharing the risk factors involved using the results of various clinical trials.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Identify the benefits and risks of adjuvant immune checkpoint inhibitor (ICI) therapy with help of case studies.
    • Recognize the differences between front-line ICI-based therapies for metastatic disease.
    • Explain the treatment options for “PD-1—refractory” disease.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    David A. Braun, MD, PhD       

    Assistant Professor, Goodman and Gilman Yale Scholar- Yale Cancer Center, Yale School of Medicine

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Consultant/Advisor/Speaker: Exelixis, AVEO, Charles River Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie.

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-305-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 12/01/2023 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: December 01, 2023

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases
    Collapse 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers

    Published: On 10/05/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.


    Estimated time to complete activity:  40 Minutes

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

    • List the multiple approaches that should be followed post treatment.

    • Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

    • Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

    • Explain the action plan for the management of toxicities associated with CAR-T cell therapies.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty and Disclosure of Conflicts of Interest

     

    Faculty
    Loretta Nastoupil, MD
    Associate Professor
    UT MD Anderson Cancer Center
    Texas, USA

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest
    Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
    Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda


    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Original Course Date: October 06, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers
    Collapse Gynecologic Cancer CPG Mini-Module 2 – A Case of Vulvar Melanoma

     

    Gynecologic Cancer CPG Mini-Module – A Case of Vulvar Melanoma

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

     

    Jyoti Bajpai, MBBS, MD, DM, of Tata Memorial Centre, Mumbai, India, presents a case study of pembrolizumab for metastatic vulvar melanoma. This case study addresses the relevance of the CPG recommendations for managing rare conditions like vulvar melanoma, necessary considerations when selecting resource-appropriate therapies in real-world situations, and studies supporting the use of supportive care or abbreviated courses of therapy when the standard of care is not available. This Mini-Module concludes with a discussion between Dr. Bajpai and Kunle Odunsi, MD, PhD, of University of Chicago Medicine on the need for more global collaboration to make immunotherapy accessible and affordable for patients around the world.

     

    Run time: Approximately 14 minutes

     

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

     

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 


     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: September 29, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gynecologic Cancer CPG Mini-Module 2 – A Case of Vulvar Melanoma
    Collapse Gynecologic Cancer CPG Mini-Module 3– Single agent immunotherapy for Cervical Cancer and Combination Therapy for Mismatch Repair-Proficient (pMMR) Endometrial Cancer

     

     

    Gynecologic Cancer CPG Mini-Module – Single agent immunotherapy for Cervical Cancer and Combination Therapy for Mismatch Repair-Proficient (pMMR) Endometrial Cancer

     

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

     

    Claire Friedman, MD, of Memorial Sloan Kettering Cancer Center presents two case studies comparing and contrasting single-agent immunotherapy and immunotherapy-based combination therapy for gynecologic cancers. The first study presented addresses pembrolizumab monotherapy for recurrent high-risk HPV-positive cervical cancer, and the second presentation discusses the use of the tyrosine kinase inhibitor lenvatinib plus pembrolizumab to treat recurrent pMMR endometrial cancer. Dr. Friedman presents the relevance of the current guidelines to these cases, key studies supporting the recommendations, clinical benefits and risks associated with single agent therapies versus combination therapies, and future challenges facing the immuno-oncology field for gynecologic cancers. Management of adverse events associated with targeted therapies and/or immunotherapies is also addressed. Dr. Friedman, Dr. Bajpai, and Dr. Odunsi conclude the Mini-Module by discussing practical approaches to promote patient tolerance of lenvatinib.

     

    Run time: Approximately 15 minutes

     

    Target Audience 

    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

     

    SITC Online Education Disclaimer 

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 



    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

    Original Course Date: September 29, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gynecologic Cancer CPG Mini-Module 3– Single agent immunotherapy for Cervical Cancer and Combination Therapy for Mismatch Repair-Proficient (pMMR) Endometrial Cancer
    Collapse Gynecologic Cancer CPG Mini Module 1 – Immunotherapy Biomarkers in the Gynecologic Tract: MMR, PD-L1, and TMB

     

    Gynecologic Cancer CPG Mini Module – Immunotherapy Biomarkers in the Gynecologic Tract: MMR, PD-L1, and TMB

     

    The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.

     

    Anne M. Mills, MD, of the University of Virginia, provides a comprehensive overview of three biomarkers associated with immunotherapy for gynecologic cancers, specifically mismatch repair (MMR), PD-L1, and tumor mutation burden (TMB). Topics discussed include immunohistochemistry- and PCR-based testing for these biomarkers, interpretation of test results, and limitations associated with these testing methods, especially in the context of gynecologic cancers. The recommendations for immunotherapy testing of biomarkers based on tumor type and studies supporting these recommendations are also discussed and summarized. The Mini-Module ends with a discussion between Dr. Mills and Nora Disis, MD, FACP, of the University of Washington on the potential of total tumor DNA sequencing for detecting biomarkers

     

    Run time: Approximately 20 minutes

     

    Target Audience
    Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants, and radiologists. 

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described
    in this educational activity. 

     

    The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

     

    The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts. 

     

    Original Course Date: September 29, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Gynecologic Cancer CPG Mini Module 1 – Immunotherapy Biomarkers in the Gynecologic Tract: MMR, PD-L1, and TMB
    Collapse 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer

    Published: On 08/11/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe key immunotherapy targets that are useful for combination approaches.
    • Describe immunotherapy-based combination treatment regimens currently under investigation.
    • Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty
    Gregory B. Lesinski, PhD, MPH
    Co-Director, Translational GI Malignancy Program
    Winship Cancer Institute of Emory University,
    Atlanta, Georgia, USA

     

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     

    Original Course Date: August 11, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers

    Published Date: 06/30/2023

    Expiration Date: 06/30/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Define the term biomarker.
    • Explain the functions of biomarkers.
    • Differentiate the biomarkers based on their types.
    • Describe the use of biomarkers in various cancer treatments.
    • Summarize the challenges of using biomarkers in the treatment of cancer.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    Dr. Paolo A. Ascierto, MD
    Director of Department of Melanoma
    UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
    Istituto Nazionale Tumori – Fondazione “G. Pascale”
    Napoli, Italy

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
    Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-162-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: June 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers
    Collapse 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)

    Published Date: 06/01/2023

    Expiration Date: 06/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Explain the Mechanisms of immune related Adverse Events in brief.
    • Describe the other host factors that affect the risk of immune related Adverse Events.
    • Summarize the differences in PD-L1 and CTLA-4 toxicities.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Pradnya Patil, MD, FACP
    Associate Staff Oncologist
    Taussig Cancer Center, Cleveland Clinic
    Cleveland, OH

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-151-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology

    Published Date: 05/05/2023

    Expiration Date: 05/05/2024

     

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 1 hour

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Chrystal M. Paulos, PhD
    Director of Translational Research, Cutaneous Malignancies
    Winship Cancer Institute at Emory University

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    IP Rights: Ares Immunotherapy
    Consulting Fees: Ares Immunotherapy
    Founder/Owner: Ares Immunotherapy
    Other (subcontracts): Obsidian, Lycera, ThermaFisher

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-142-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 05, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology
    Collapse 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy

    Published: On 04/28/2023

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe the concept of Immunotherapy.
    • Identify the various types of cancer immunotherapy.
    • Describe the rationale for common approaches to cancer immunotherapy.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

     

    Faculty
    Christian M. Capitini, MD
    Associate Professor
    University of Wisconsin-Madison

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


     

     

    Original Course Date: April 28, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy
    Collapse Advanced Kidney Cancer: Know Your Treatment Options

    Access Course

    This article is for people who have advanced kidney cancer and their caregivers, or anyone who wants to learn more about advanced kidney cancer. The goal of this activity is to help people engage in shared decision-making with their doctor about treatment.

     

     

     

     

    In this course, you will learn about:

    • What advanced kidney cancer is
    • Making a treatment plan with your doctor
    • Treatment options for advanced kidney cancer
    • Possible side effects of treatment
    • Questions to ask your doctor

    Available beginning: February 24, 2022

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 24, 2022
    MORE INFOMORE INFO Advanced Kidney Cancer: Know Your Treatment Options
    Collapse Patient Course: Understanding Cancer Immunotherapy - Fifth Edition

    Course Description

    This easy-to-use, interactive course provides patients and caregivers with many resources and basic education on cancer and immunotherapy. The course is designed to be self-directed and is based on the Understanding Cancer Immunotherapy - 5th Edition Patient Resource Guide. There are five modules offered, and learners can access one or all of the modules, depending upon their interest level for each topic: 

     

    first_screen_2.png

     

     

     

     

     

     

     

     

     

     

     

     

    Module Content

    Your Treatment and Providers - This module talks about how cancer treatment may proceed, including what tests a patient may undergo, what doctors may look for to determine the best treatment options, and healthcare providers that are involved in cancer care. It also provides links to SITC resources by type of cancer.

    Cancer and The Immune System - This module provides education on what cancer is, why it forms, how it relates to the immune system as well as how it can evade the immune system. This is a helpful precursor to the Types of Immunotherapy module which explains how different immunotherapies work.

    Types of Immunotherapies - This module has interactive animations that help describe how different types of cancer immunotherapy work to treat cancer. In addition, there is an infographic of the FDA-approved cancer immunotherapies by disease.

    The Importance of Reporting Side Effects - This module discusses possible side effects of cancer immunotherapy and stresses why it is important to report side effects to care providers. It also provides links to more resources on this topic.

    Empower Yourself With Patient Resources - This module has many links to a wide variety of resources, including financial assistance resources, clinical trial search engines, patient/caregiver support groups and more information and courses by disease type.

     

     

    Target Audience

    This activity is intended for cancer patients and their caregivers.

     

    Educational Objectives

    After completing this activity, the participant should:

    • Have an improved understanding of cancer immunotherapy.
    • Be able to find and access support and resources relevant to their cancer and/or situation. 

     

    Available Beginning:  5/30/19

    Approximate time to complete: 30 minutes

     

    This online patient education activity was produced with the generous support of the following companies.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.




     

    Original Course Date: May 30, 2019
    MORE INFOMORE INFO Patient Course: Understanding Cancer Immunotherapy - Fifth Edition
    Collapse Management of Advanced Bladder Cancer: What You Should Know

    Access Course

     

    This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

     

     

     

     

     

    You will learn about:

     

    • What chemotherapy is and how it is used to treat advanced bladder cancer
    • What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
    • The potential side effects of chemotherapy and checkpoint inhibitors
    • Why the side effects from chemotherapy and checkpoint inhibitors are different
    • Questions to ask your doctor

     

    Available beginning: April 26, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 26, 2019
    MORE INFOMORE INFO Management of Advanced Bladder Cancer: What You Should Know


    Patient Courses by Cancer Type